Terns Pharmaceuticals $53 Cash Sale to Merck Faces Fiduciary Probe
The planned sale of Terns Pharmaceuticals to Merck for $53.00 per share is under scrutiny for potential breaches of fiduciary duty that could grant insiders disproportionate benefits. Shareholders are being advised to explore legal options on a contingent fee basis to seek increased consideration or additional disclosures.
1. Proposed Merck Acquisition
Terns Pharmaceuticals has agreed to be acquired by Merck in a cash deal worth $53.00 per share, representing a premium to its recent trading levels.
2. Fiduciary Breach Allegations
Investor rights counsel is investigating potential breaches of fiduciary duties and deal provisions that may favor insiders and restrict superior competing offers.
3. Shareholder Rights and Remedies
Shareholders are encouraged to seek legal advice on a contingent fee basis to pursue increased deal consideration, additional disclosures or other relief.